Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board

February 20, 2024

https://www.globenewswire.com/news-release/2024/02/20/2831823/24825/en/Codexis-Announces-Appointment-of-Masad-Damha-PhD-and-Jim-Lalonde-PhD-to-Strategic-Advisory-Board.html

REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder and former Chief Executive Officer of Alnylam Pharmaceuticals. This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company’s strategic direction, providing critical insights to inform the continued development of Codexis’ ECO Synthesis™ manufacturing platform.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.